Key stats
About iShares Genomics Immunology and Healthcare ETF
Home page
Inception date
Jun 11, 2019
Structure
Open-Ended Fund
Replication method
Physical
Dividend treatment
Distributes
Distribution tax treatment
Qualified dividends
Income tax type
Capital Gains
Max ST capital gains rate
39.60%
Max LT capital gains rate
20.00%
Primary advisor
BlackRock Fund Advisors
Distributor
BlackRock Investments LLC
IDNA holds a concentrated portfolio of global companies in the biopharmaceutical and healthcare equipment and services industries that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. In addition to these industry screens, companies must also meet certain size and liquidity measures for index eligibility. The underlying index then assigns a Relationship Keyword Score to each of the eligible companies using the FactSet Supply Chain Relationships database in search for keywords related to Genomics and Immuno Biopharmaceutical products and technologies. The top 50 names with the highest scores are included in the index. Holdings are weighted by market-cap and are constrained such that no individual security exceeds 4% weight of the portfolio. The index rebalances semi-annually.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Stocks99.82%
Health Technology98.98%
Health Services0.83%
Bonds, Cash & Other0.18%
Cash0.18%
Stock breakdown by region
North America63.26%
Europe30.33%
Asia6.41%
Latin America0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings
Dividends
Dividend payout history
Assets under management (AUM)
Fund Flows
Frequently Asked Questions
IDNA invests in stocks. The fund's major sectors are Health Technology, with 98.98% stocks, and Health Services, with 0.83% of the basket. The assets are mostly located in the North America region.
IDNA top holdings are BeOne Medicines Ltd. and Moderna, Inc., occupying 4.76% and 4.74% of the portfolio correspondingly.
IDNA last dividends amounted to 0.15 USD. Six months before that, the issuer paid 0.11 USD in dividends, which shows a 27.37% increase.
IDNA assets under management is 110.49 M USD. It's risen 4.53% over the last month.
IDNA fund flows account for −16.10 M USD (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.
Yes, IDNA pays dividends to its holders with the dividend yield of 1.24%. The last dividend (Jun 20, 2025) amounted to 0.15 USD. The dividends are paid semi-annually.
IDNA shares are issued by BlackRock, Inc. under the brand iShares. The ETF was launched on Jun 11, 2019, and its management style is Passive.
IDNA expense ratio is 0.47% meaning you'd have to pay 0.47% of your investment to help manage the fund.
IDNA follows the NYSE FactSet Global Genomics and Immuno Biopharma Index. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
IDNA invests in stocks.
IDNA price has risen by 3.61% over the last month, and its yearly performance shows a −14.74% decrease. See more dynamics on IDNA price chart.
NAV returns, another gauge of an ETF dynamics, showed a 10.18% increase in three-month performance and has decreased by −13.90% in a year.
NAV returns, another gauge of an ETF dynamics, showed a 10.18% increase in three-month performance and has decreased by −13.90% in a year.
IDNA trades at a premium (0.10%) meaning the ETF is trading at a higher price than the calculated NAV.